Impact of Cardiac Dose on Cardiac Events and Survival in Unresectable Lung Cancer Patients

Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC

“…Other studies found weak or no associations between cardiac doses and cardiac events. [30][31][32] The median follow-up for our cohort was 47.4 months, which we believe led to a more accurate reflection of cardiotoxicity. Pertinent studies on RT-associated cardiotoxicity for inoperable NSCLC are summarized in Supplementary Table 3.…”

“…Although prior studies have shown a cardiac dosetoxicity relationship among patients with inoperable NSCLC receiving dose-escalated RT (median prescribed doses, 70 to 74 Gy 3,4,14,29 ), the evidence remains limited and conflicting among patients treated with more conventional RT doses (median prescribed doses, 60 to 66 Gy). 10,14,[30][31][32] Speirs et al 10 found that higher cardiac doses were associated with worse OS and grade 1 cardiotoxicities. However, they found no association between cardiotoxicities and OS, perhaps because the most common cardiotoxicity was pericardial effusions incidentally noted on follow-up imaging.…”